Skip to main content

Table 3 Efficacy outcomes by tumor HER2 expression below the median and equal to or greater than the median

From: Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

  Median PFS, months  
HER2 expressiona HT T-DM1 HR relative to HT (95% CI)
  All patients (n = 70) (n = 67) 0.59 (0.36, 0.97)
9.2 14.2
  < Median (n = 32) (n = 26) 0.85 (0.44, 1.67)
9.8 10.6
  ≥ Median (n = 29) (n = 29) 0.39 (0.18, 0.85)
8.8 Not reached
  ORR,%  
HER2 expression a HT T-DM1 Odds ratio relative to HT (95% CI)
  All patients (n = 69) (n = 67) 1.26 (0.63, 2.55)
58.0 64.2
  < Median (n = 31) (n = 26) 0.84 (0.30, 2.41)
58.1 53.8
  ≥ Median (n = 29) (n = 29) 1.58 (0.50, 4.98)
65.5 72.4
  1. aHER2 mRNA data were available for 61 of 70 patients in the HT arm and for 55 of 67 patients in the T-DM1 arm. HER2, human epidermal growth factor receptor 2; HT, trastuzumab plus docetaxel; ORR, objective response rate; PFS, progression-free survival; T-DM1, trastuzumab emtansine.